Sep. 11 at 2:28 PM
$HROW Baum highlighted the acquisition terms for TYRVAYA, noting they secured the global rights at less than 1x trailing revenue (
$30M upfront) in an industry where dry-eye assets routinely trade at 7x to 10x revenue. He reiterated that TYRVAYA’s existing broad commercial coverage will be leveraged to pull VEVYE onto more formularies.
Reaffirming the
$1B Run-Rate (
$250M/Quarter) for 2027:
Management firmly kept their
$250 million quarterly revenue goal for calendar 2027 on the table. Baum reminded the institutional audience that when Harrow initially set a
$100M revenue run-rate target years ago, critics called it impossible—yet they hit it right on schedule.
